Fresh Tracks cuts costs, mum on status of merger exploration

BOULDER — Fresh Tracks Therapeutics Inc., the Boulder-based pharmaceutical company formerly called Brickell Biotech, cut its net loss from the first quarter of 2022 in half during the most recent period, one in which the company continued the process of exploring its strategic options for a merger or sale.

The company, which has a pair of autoimmune and inflammatory disease treatments in the pipeline and negligible revenue, posted a net loss of $4.3 million in the first quarter this year, down from a loss of $9.4 million for the first quarter of 2022.

The cost reduction came largely from decreased research…